Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 Study of Doravirine/Islatravir 100 mg/0.25 mg in Prior DOR/ISL Recipients
2022-502126-40-00Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, open-label, single-arm trial of doravirine and islatravir in Human immunodeficiency virus infection type 1, sponsored by Merck & Co. Primary endpoints: Percentage of participants with one or more adverse events and Percentage of participants who discontinue study intervention due to adverse events. Planned start Apr 2023; status: withdrawn.
02
Drugs
doravirineislatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2022-502126-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502126-40-00.